CytRx Corporation (NASDAQ:CYTR) and Recro Pharma Inc. (NASDAQ:REPH), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations of the two firms.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Recro Pharma Inc.||77.35M||2.62||79.72M||-3.83||0.00|
Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of CytRx Corporation and Recro Pharma Inc.
Table 2 demonstrates the return on equity, net margins and return on assets of CytRx Corporation and Recro Pharma Inc.
|Net Margins||Return on Equity||Return on Assets|
|Recro Pharma Inc.||-103.06%||-739.7%||-46.2%|
Risk and Volatility
CytRx Corporation’s current beta is 2.2 and it happens to be 120.00% more volatile than Standard & Poor’s 500. Recro Pharma Inc. on the other hand, has -0.29 beta which makes it 129.00% less volatile compared to Standard & Poor’s 500.
The current Quick Ratio of CytRx Corporation is 3.1 while its Current Ratio is 3.1. Meanwhile, Recro Pharma Inc. has a Current Ratio of 2.5 while its Quick Ratio is 2.1. CytRx Corporation is better positioned to pay off its short-term and long-term debts than Recro Pharma Inc.
The Recommendations and Ratings for CytRx Corporation and Recro Pharma Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Recro Pharma Inc.||0||0||2||3.00|
Meanwhile, Recro Pharma Inc.’s consensus target price is $19, while its potential upside is 105.63%.
Institutional and Insider Ownership
Institutional investors owned 10.2% of CytRx Corporation shares and 70.5% of Recro Pharma Inc. shares. 8.5% are CytRx Corporation’s share owned by insiders. On the other hand, insiders owned about 1.3% of Recro Pharma Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Recro Pharma Inc.||13.15%||15.2%||39.01%||51.83%||-4.4%||34.51%|
For the past year CytRx Corporation’s stock price has bigger growth than Recro Pharma Inc.
CytRx Corporation beats on 8 of the 10 factors Recro Pharma Inc.
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The companyÂ’s product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi’s sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. Its lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain. It also provides contract development and manufacturing services. It has a license agreement with Orion Corporation for the development and commercialization of Non-Injectable Dexmedetomidine. The company focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.